Structure Therapeutics (GPCR) Reports Positive Phase 2 Weight Loss Data for Aleniglipron

Structure Therapeutics Inc. (NASDAQ:GPCR) is one of the oversold stocks to buy right now. Structure Therapeutics reported positive Phase 2 results for its oral GLP-1 receptor agonist, aleniglipron, showing up to 16.3% weight loss. With favorable FDA feedback, the company is on track to initiate a Phase 3 registrational trial in Q3 2026.

The company is also advancing its oral amylin receptor agonist pipeline, with lead candidate ACCG-2671 expected to enter multiple ascending dose studies in Q3 and a second candidate, ACCG-3535, beginning clinical trials in Q4. These programs aim to provide accessible oral small-molecule treatments for metabolic diseases.

Structure Therapeutics (GPCR) Reports Positive Phase 2 Weight Loss Data for Aleniglipron

Financially, Structure Therapeutics Inc. (NASDAQ:GPCR) holds $1.5 billion in cash, providing a runway through 2028 to support its clinical programs. Detailed updates on its aleniglipron and amylin portfolios are scheduled for presentation at the American Diabetes Association’s scientific sessions this June.

Structure Therapeutics Inc. (NASDAQ:GPCR) is involved in the development and marketing of novel oral small molecule therapies for the treatment of several chronic diseases with unmet medical needs.

While we acknowledge the risk and potential of GPCR as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than GPCR and that has 10,000% upside potential, check out our report about the cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1